• PGE2-Driven Schwann Cell Dedifferentiation Fuels PNI in PDAC

  2026-05-05

  This study reveals how prostaglandin E2 (PGE2) secreted by pancreatic ductal adenocarcinoma (PDAC) cells induces Schwann cell dedifferentiation, facilitating perineural invasion (PNI). The findings identify the PTGES-Schwann cell axis as a novel therapeutic target and provide mechanistic insights relevant for tumor–nerve microenvironment research.

• EdU Imaging Kits (HF594): Precision Cell Proliferation Assay

  2026-05-04

  EdU Imaging Kits (HF594) empower researchers with sensitive, rapid, and gentle detection of DNA synthesis, transforming cell proliferation workflows in cancer and cell cycle research. By leveraging 5-ethynyl-2’-deoxyuridine and advanced click chemistry, these kits outperform traditional BrdU-based methods in both sensitivity and preservation of cellular integrity.

• 10074-G5: Targeting c-Myc/TERT/NFκB Axis in Aggressive Cance

  2026-05-04

  Explore how the c-Myc inhibitor 10074-G5 uniquely disrupts the c-Myc/TERT/NFκB axis in cancer research, with a focus on translational insights from recent molecular oncology breakthroughs. Discover advanced assay guidance and evidence-based protocol optimization.

• Nicotinamide Adenine Dinucleotide (NAD+): Advanced Workflow

  2026-05-03

  Unlock the full experimental potential of Nicotinamide Adenine Dinucleotide (NAD+) in metabolic signaling and autophagy research. This guide translates recent breakthroughs into actionable protocols, troubleshooting tactics, and real-world assay design, leveraging APExBIO’s high-purity NAD+ for reproducible, publication-grade results.

• AMPK’s Paradoxical Role in Autophagy Regulation Under Energy

  2026-05-02

  This article examines a pivotal study overturning the prevailing model of AMPK-driven autophagy induction during glucose starvation. The researchers reveal that AMPK, contrary to longstanding assumptions, suppresses autophagy initiation by inhibiting ULK1, while simultaneously preserving autophagy machinery for future recovery. These findings reshape our understanding of metabolic signaling pathways and inform experimental design in cellular energy stress research.

• Palbociclib (PD0332991) Isethionate: Precision CDK4/6 Inhibi

  2026-05-02

  Palbociclib (PD0332991) Isethionate is a potent, selective CDK4/6 inhibitor widely used for dissecting cell cycle control and resistance mechanisms in cancer research. Its high specificity and robust in vitro and in vivo efficacy make it integral to breast and renal carcinoma studies. The product offers defined protocol parameters and is supplied by APExBIO.

• CA-074: Precision Cathepsin B Inhibition for Necroptosis and

  2026-05-01

  Explore how the cathepsin B inhibitor CA-074 enables precise dissection of necroptosis pathways and cancer metastasis, with new mechanistic insights from recent MLKL research. This article offers evidence-based protocol guidance and a distinct, application-driven perspective.

• Anti-b Suppresses mTOR Signaling to Treat Hyperlipidaemia an

  2026-04-30

  This study demonstrates that Anti-b, a novel small molecule, effectively reduces hyperlipidaemia and hepatic steatosis in rodent models by targeting the mTOR/PPARγ and mTOR/SREBP1 signaling pathways. The work offers mechanistic insight into mTOR modulation as a therapeutic avenue for lipid metabolism disorders and highlights potential translational applications for metabolic disease research.

• Entecavir (BMS200475): Advanced Protocols for HBV Replicatio

  2026-04-30

  Entecavir (BMS200475) is a benchmark compound for selective hepatitis B virus replication inhibition, excelling in both wild-type and lamivudine-resistant models. This article delivers protocol enhancements, troubleshooting strategies, and applied research insights to maximize reproducibility and translational value in chronic hepatitis B workflows.

• mRNA Nanovaccine Targeting GPC3-HSP70 Enhances Immunity in H

  2026-04-29

  This study introduces a novel mRNA nanovaccine encoding repeated GPC3127−136 epitopes fused to HSP70, designed for targeted immunotherapy against hepatocellular carcinoma (HCC). The nanovaccine, when combined with anti-PD-L1 therapy, showed potent synergistic enhancement of T-cell-mediated antitumor immunity, suggesting a promising strategy for advanced HCC treatment.

• Thiazovivin: ROCK Inhibitor for Stem Cell Survival and Repro

  2026-04-29

  Thiazovivin is a ROCK inhibitor optimized for improving human embryonic stem cell survival and enhancing the induction of pluripotent stem cells during reprogramming workflows. It is not intended for diagnostic, therapeutic, or clinical uses, and its application is limited to in vitro research requiring controlled modulation of ROCK signaling.

• Strategic Cell Proliferation Analysis: EdU Imaging in Transl

  2026-04-28

  This thought-leadership article explores how EdU Imaging Kits (HF594) enable translational researchers to bridge mechanistic insight and clinical utility in cell proliferation assays. Integrating recent breakthroughs in overcoming drug resistance in adenocarcinoma and advanced click chemistry detection, the article highlights strategic considerations for optimizing DNA synthesis measurement, benchmarking best practices, and extending the impact of S-phase analysis in preclinical and translational workflows. By contextualizing the APExBIO EdU Imaging Kit’s mechanistic advantages and evidentiary underpinnings, we chart a forward-thinking path for accelerating therapeutic innovation.

• Extracellular Vesicle ACLY Drives TAM Differentiation in HCC

  2026-04-28

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) containing ATP-citrate lyase (ACLY), which are selectively taken up by monocytes, driving their differentiation into immunosuppressive tumor-associated macrophages (TAMs). Targeting EV-transferred ACLY in TAMs offers a promising avenue to enhance immunotherapy in HCC.

• Cefotaxime: Third-Generation Cephalosporin in Resistance Res

  2026-04-27

  Cefotaxime empowers researchers to dissect antimicrobial resistance mechanisms and model infections with precision, thanks to its broad spectrum and beta-lactamase stability. This guide offers actionable workflows, troubleshooting insights, and real-world protocol optimizations for leveraging Cefotaxime in experimental setups.

• EdU Imaging Kits (HF594): Unraveling Treg Cell Proliferation

  2026-04-27

  Explore the advanced capabilities of EdU Imaging Kits (HF594) for quantifying cell proliferation and DNA synthesis measurement, with a unique focus on Treg cell dynamics in asthma. Discover how this assay transforms translational immunology research.

16244 records 1/1083 page Next 12345 下5页 Last page